• PDF / 169,654 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 91 Downloads / 179 Views

DOWNLOAD

REPORT

---

1 S

Intracranial meningioma: case report A 39-year-old woman developed intracranial meningioma following treatment with glatiramer-acetate and interferon-beta-1a for relapsing-remitting multiple sclerosis (RRMS) [routes not stated; not all dosages stated]. The woman had a month history of diplopia followed by paresthesia and 8 months later weakness in the left upper limb. Additionally, she also paraparesis with sphincter impairment, bouts of vertigo, weakness of the right hand and left facial paralysis. Base on various investigations she was diagnosed with RRMS. Then, she started receiving treatment with interferon beta-1a 22mg three times a week. After 7 years, the woman’s immunomodulatory therapy with interferon-beta-1a was switched to glatiramer acetate due to elevated levels of serum liver enzymes. However 3 years later, a routine brain MRI revealed a gadolinium-enhanced round lesion in the basal part of the left frontal lobe, with typical appearance of meningioma, with characteristic demyelinating lesions seen in RRMS. The intracranial meningioma was asymptomatic. Her Goldmann perimetry was unrevealing and expanded disability status scale score was 1. Thus, development of intracranial meningioma was attributed to administration of glatiramer-acetate and interferon-beta-1a [time to reactions onsets and outcomes not stated]. Vieira RGK, et al. Meningioma after immunomodulation for multiple sclerosis. Arquivos de Neuro-Psiquiatria 70: 75-76, No. 1, Jan 2012. Available from: URL: http:// 803499983 doi.org/10.1590/S0004-282X2012000100017

0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Sep 2020 No. 1820